7210 Wareham Drive, Tampa, FL 33647
April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest […]
Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »
March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can
FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »
March 5, 2025 Weight loss drugs (GLP-1s) have soared in popularity over the last two years, with about 12% of American adults reporting that they’ve used a medication like Ozempic, Wegovy or Mounjaro to slim down. That’s a big slice of the population — and new research shows that being on these medications influences what
GLP-1 Drugs Are Affecting Consumers’ Food Spending Habits Read More »
Feb. 27, 2025 WW reported its Q4 and full year 2024 results today. The company’s Board of Directors named Interim President and CEO Tara Comonte, to a permanent role as President and CEO, effective February 26, 2025. “We are pleased with the momentum in our Clinical business in the Fourth Quarter, reflecting the increasing demand
Weight Watchers Reports Q4 and 2024 Yearly Results Read More »
Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing
$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »
Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at
Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »
Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed
Conflicts in Trump Administration For Support of GLP-1 Meds Read More »
January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the
The Party Is Almost Over for GLP-1 Compounders Read More »
Dec. 20, 2024 The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. Zepbound is FDA-approved to treat obesity and Mounjaro is approved for diabetes. They
FDA Says Shortage Is Over, Compounders Have 60-90 Days Read More »
Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists
Zepbound Beats Wegovy for Weight Loss Read More »